Please Note: This trial is no longer enrolling new participants
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
| Protocol No. | CTO-MK-3475-866 | Scope | National |
|---|---|---|---|
| Principal Investigator | Nabil Adra | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
